CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleLevered free cash flow is $33.46M, above the global median of $16.24M
- FinancialsAltman Z-Score 9.48: safe zone
- Interpretations8 currently firing — 8
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
648.27MUSDvs all stocks (USD)
Trailing P/E
33.03xvs Medical Devices peers
Revenue (TTM)
343.52MUSDvs all stocks (USD)
Profit Margin
5.91%vs Medical Devices peers
Beta
0.7910xvs all stocks
52-Week Change
197.51%vs all stocks
Market Capitalization
648.27MUSDvs all stocks (USD)
Enterprise Value
588.45MUSDvs all stocks (USD)
Trailing P/E
33.03xvs Medical Devices peers
Forward P/E
19.10xvs Medical Devices peers
PEG Ratio
-0.8589xvs Medical Devices peers
Price to Sales (TTM)
1.89xvs Medical Devices peers
Price to Book (MRQ)
3.00xvs Medical Devices peers
Enterprise to Revenue
1.71xvs Medical Devices peers
Enterprise to EBITDA
15.15xvs Medical Devices peers
Gross Margin
76.55%vs Medical Devices peers
Profit Margin
5.91%vs Medical Devices peers
Operating Margin
-2.04%vs Medical Devices peers
Return on Assets (TTM)
7.31%vs Medical Devices peers
Return on Equity (TTM)
9.59%vs Medical Devices peers
Revenue (TTM)
343.52MUSDvs all stocks (USD)
Revenue per Share (TTM)
15.21USDUpdated Jul 19, 2026Quarterly Revenue Growth
22.80%vs Medical Devices peers
Gross Profit (TTM)
262.41MUSDvs all stocks (USD)
EBITDA (TTM)
41.71MUSDvs all stocks (USD)
Net Income (TTM)
20.30MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
22.85%vs Medical Devices peers
Operating Cash Flow (TTM)
42.05MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
33.46MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
329.52MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
79.38MUSDFY2025 · Dec 31, 2025Gross Profit
250.15MUSDFY2025 · Dec 31, 2025Operating Income
29.28MUSDvs all stocks (USD)
Pre-tax Income
31.34MUSDFY2025 · Dec 31, 2025Income Tax Expense
12.25MUSDFY2025 · Dec 31, 2025Net Income
19.09MUSDFY2025 · Dec 31, 2025EBIT
32.38MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
39.02MUSDFY2025 · Dec 31, 2025Research & Development
8.48MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
209.94MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.10MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.04MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.8300USDFY2025 · Dec 31, 2025EPS (Diluted)
0.8200USDFY2025 · Dec 31, 2025Basic Shares Outstanding
22.87MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
22.87MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
19.09MUSDFY2025 · Dec 31, 2025Operating Cash Flow
46.20MUSDFY2025 · Dec 31, 2025Free Cash Flow
43.82MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
83.45MUSDFY2025 · Dec 31, 2025Income Tax Paid
2.50MUSDFY2025 · Dec 31, 2025Interest Paid
1.22MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
19.09MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
6.64MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
8.53MUSDFY2025 · Dec 31, 2025Stock-based Compensation
8.36MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.06MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-758.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
3.29MUSDFY2025 · Dec 31, 2025Capital Expenditures
-2.38MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-2.38MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-26.25MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-26.56MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-52.81MUSDFY2025 · Dec 31, 2025Shares Outstanding
22.71MSharesUpdated Jul 19, 2026Float Shares
22.08MSharesUpdated Jul 19, 2026Shares Short
2.44MSharesUpdated Jul 19, 2026Short Ratio
9.34daysvs all stocks
Short % of Shares Outstanding
11.01%vs all stocks
% Held by Insiders
2.31%vs all stocks
% Held by Institutions
103.13%vs all stocks
Total Cash (MRQ)
74.99MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.33USDUpdated Jul 19, 2026Total Debt (MRQ)
15.17MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0697xvs Medical Devices peers
Current Ratio (MRQ)
4.24xvs Medical Devices peers
Book Value per Share (MRQ)
9.59USDUpdated Jul 19, 2026Total Assets
273.94MUSDvs all stocks (USD)
Total Current Assets
165.17MUSDFY2025 · Dec 31, 2025Total Liabilities
55.04MUSDFY2025 · Dec 31, 2025Total Non-current Assets
108.78MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
14.08MUSDFY2025 · Dec 31, 2025Total Current Liabilities
40.96MUSDFY2025 · Dec 31, 2025Cash
83.45MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
83.45MUSDFY2025 · Dec 31, 2025Other Short-term Investments
15.75MUSDFY2025 · Dec 31, 2025Accounts Receivable
43.88MUSDFY2025 · Dec 31, 2025Inventory
14.03MUSDFY2025 · Dec 31, 2025Accounts Payable
4.97MUSDFY2025 · Dec 31, 2025Short-term Debt
3.19MUSDFY2025 · Dec 31, 2025Other Current Liabilities
3.46MUSDFY2025 · Dec 31, 2025Long-term Debt
12.76MUSDFY2025 · Dec 31, 2025Common Stock (Book)
22.00KUSDFY2025 · Dec 31, 2025Retained Earnings
54.94MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
218.90MUSDvs all stocks (USD)
52-Week Low
9.41USDUpdated Jul 19, 202652-Week High
37.77USDUpdated Jul 19, 202652-Week Change
197.51%vs all stocks
Beta
0.7910xvs all stocks
50-Day MA
26.67USDUpdated Jul 19, 2026200-Day MA
25.46USDUpdated Jul 19, 2026Avg 10-Day Volume
217.74KSharesUpdated Jul 19, 2026Avg 30-Day Volume
245.33KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
0.8700USDUpdated Jul 19, 2026Other Income / Expense
1.00KUSDFY2025 · Dec 31, 20258 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Diagnostic
High OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-Deceleration
Cash covers reported profit and gross profit is up, with margins high and growth slowing.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Low Fixed-Asset Share With Elevated Turnover
It owns few buildings and machines, yet gets more sales and profit from its assets than its industry does.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.77Profit Margin: 0.06
Financial Health
Altman Z-Score 9.48: safe zoneNotable
Altman Z-Score: 9.48
High earnings qualityNotable
Earnings Quality Score: 1.13
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Levered free cash flow is $33.46M, above the global median of $16.24MNotable
Levered free cash flow (USD): 33,462,124Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
476830
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Neptunus Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jianmin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hefei Lifeon Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhongzhu Healthcare Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lionco Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
MiMedx Group, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sinotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
LivsMed Inc.
Tier 1ProductionApproval-Gated PipelineRule
CorMedix Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Puma Biotechnology Inc.
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow Fixed-Asset Share With Elevated Turnover
XPEL, Inc.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow Fixed-Asset Share With Elevated TurnoverMulti-Year FCF With Growth And Margin
MiMedx Group, Inc.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow Fixed-Asset Share With Elevated TurnoverMulti-Year FCF With Growth And MarginMulti-Year Debt Decrease With Cash Near Total Debt And Equity